Introduction {#s1}
============

The cell types transit in human body, which is identified by molecular profiles and contributes into the human disease ([@B58]). Epithelial-mesenchymal transition (EMT) is defined as cellular phenotypic changes from epithelial to mesenchymal type with high expression of N-cadherin and vimentin, which occurs in various conditions including normal and cancer cells([@B76]; [@B49]). The EMT plays various roles in the cellular processes such as migration, extracellular matrix (ECM) alteration and apoptosis ([@B68]; [@B54]). EMT is also known to drive cell plasticity and contributes in intra-tumor heterogeneity ([@B34]; [@B87]). Cancer poses the entity-specific differences and variety of populations in different malignant stages ([@B12]; [@B18]). Cancer stem cell (CSC), stem cell population in cancer, is detected with markers such as CD44, while the distinct markers for CSC have not been determined, so far ([@B91]; [@B20]). Two possibilities for cancer generation, such as the stochastic model and hierarchy model, have been long discussed and are still controversial. CSCs consist of cancer cells with stem-like features, which have capacities of self-renewal, differentiation in cancer cells ([@B61]). It is also known that some population of CSCs shares the EMT-like cell features ([@B66]). The potential link between EMT and CSCs is a key to cancer drug resistance acquisition, as well as cancer cell plasticity in which the cancer cells transform into the malignant cells and *vice versa* ([@B41]). To reveal the mechanism of cancer drug resistance, the features of EMT and CSCs should be investigated. The CSCs express transporters on their cell membrane to transport anticancer drugs from inside to outside of the cells ([@B62]; [@B6]). The gene and protein expression of the transporters are altered in the CSCs, which may contribute to the acquisition of drug resistance([@B38]).

The Role and Regulation of EMT {#s2}
==============================

The Gene Modules and Network-Based Approaches for EMT-Regulated Genes {#s2_1}
---------------------------------------------------------------------

EMT controls various cellular processes such as migration, invasion, metastasis, ECM alteration, and apoptosis ([@B68]; [@B54]). EMT is implicated in the cancer malignancy, and many genes such as NOTCH family genes are regulated as comparing mesenchymal stem cells (MSCs) and diffuse-type gastric cancer ([@B73]; [@B74]). Gene expression of E-cadherin (cadherin1; CDH1) and N-cadherin (cadherin2; CDH2), as well as vimentin are altered in diffuse-type gastric cancer and MSCs ([@B72]). Molecular networks are regulated in EMT, which is a critical process in cancer metastasis and malignancy ([@B77]; [@B78]; [@B79]; [@B80]; [@B75]). Network-based approach has revealed the several transcription factors predicting diagnosis and drug response in colorectal cancer, which may contribute into the whole understanding of the EMT-regulated mechanisms ([@B4]; [@B80]).

The Signaling Pathways in EMT {#s2_2}
-----------------------------

Several signaling pathways such as estrogen receptor signaling, androgen receptor signaling, transforming growth factor beta (TGF-β) signaling and epidermal growth factor (EGF) signaling are involved in EMT in prostate cancer ([@B46]). The EMT feature is also involved in resistance in antiandrogen therapy for prostate cancer ([@B46]). transforming growth factor beta (TGF-β) signaling, Sonic Hedgehog (SHH) signaling, and WNT signaling pathways are involved in EMT relating development, wound healing and cancer ([@B94]). The molecules targeting the signaling related to EMT signaling are anticancer drug candidates, in which the trabedersen (AP12009) inhibiting TGF-β2 expression has been developed for pancreatic cancer treatment, SB431542 inhibiting TGF-β receptor I is used for breast cancer therapy, and LY2109761, another TGF-β receptor inhibitor has been developed for pancreatic cancer treatment ([@B45]; [@B81]; [@B65]; [@B94]). Fresolimumab, a human anti-TGF-β monoclonal antibody was applied for the treatment in advanced malignant melanoma and renal cell carcinoma patients in Phase I study, which resulted in the acceptable safety and preliminary evidence of antitumor activity ([@B48]). TGF-β signaling is also targeted in the glioma treatment ([@B23]). It has been revealed that TGF-β signaling and EGF signaling pathways play critical roles in the regulation of the metastasis of aggressive breast cancer ([@B90]).

Regulation of EMT by MicroRNAs {#s2_3}
------------------------------

MicroRNAs (miRNAs) are highly conserved, small noncoding, single-stranded RNAs of 20--25 nucleotides that suppress the expression of target genes by translational repression, mRNA degradation, or both ([@B67]). To date, 1,917 miRNAs are reported in the human genome (GRCh38) ([@B33]). A single miRNA usually has multiple target genes with partially complementary mRNA sequences, while a single gene can be regulated by several miRNAs ([@B29]). miRNAs play important roles in the various biological processes, including differentiation, proliferation, apoptosis, and progression of tumors ([@B93]). In the process of progression of tumors, EMT plays crucial roles in tumor invasion and metastasis. Increasing evidence supports that miRNAs are associated with EMT. A subset of miRNAs (miR-187, miR-34a, miR-506, miR-138, miR-30c, miR-30d, miR-30e-3p, miR-370, and miR-106a) were found to either enhance or suppress the ovarian carcinoma-associated EMT ([@B32]). Reduced expression levels of the miR-200 family (miR-200a, miR-200b, miR-200c, miR-141, and miR-429) in breast cancer upregulated ZEB1/ZEB2, activating TGF-β/BMP signaling to promote EMT ([@B63]). It was reported that the overexpression of miR-200 family could inhibit EMT through the direct suppression of ZEB1/ZEB2 and increases the sensitivity of cancer cells to chemotherapeutic agents ([@B21]; [@B19]). miR-655 was reported as both an EMT-suppressive miRNA and a predictor for poor prognosis in esophageal squamous cell carcinoma ([@B24]). It was also reported that overexpression of miR-509-5p and miR-1243 increased the expression of E-cadherin through the suppression of EMT-related gene expression and that drug sensitivity increased with a combination of each of these miRNAs and gemcitabine ([@B25]). These reports suggest that miRNAs are one of the promising tools to regulate EMT.

Linkage Between EMT and CSCs {#s3}
============================

Regulation in EMT and CSC Pathways {#s3_1}
----------------------------------

EMT and CSC pathways are regulated at gene level in different pathways such as MAPK/ERK, TGFβ-SMAD, JAK/STAT, PI3K-AKT-NFκB, and WNT/β-catenin pathways ([@B41]). [**Figure 1**](#f1){ref-type="fig"} shows the complexity model scheme for the linkage between EMT and CSC concept. Diverse genes are involved in cancer phenotypes and heterogeneity, which defines the subtypes of breast cancer ([@B60]). Immune modulatory effect has been reported in EMT and CSCs, which realized the immunotherapy targeting cancer immunity ([@B15]; [@B11]; [@B64]). EMT and CSC properties are involved in the resistance to cytotoxic T lymphocytes ([@B82]). Tumor-associated macrophages resides in the microenvironment of the cancer contributes to the EMT characterization ([@B37]). EMT and CSCs are implicated in cellular senescence ([@B14]; [@B50]). The cellular senescence can be targeted in terms of the acquisition of stemness of CSCs in cancer therapy ([@B14]; [@B50]). The senescence of CSCs is also one of the major reasons of the anticancer treatment which inhibits the cell division ([@B14]; [@B50]). The tumor dormancy is one of the major factors of therapy resistance mediated by CSCs ([@B69]). There is controversially interesting discussion that the dormant tumor cells which acquire EMT phenotypes promote the metastatic proliferation of the cells in CSC-like phenotypes ([@B89]). Moreover, in the metastasis process, cytoskeletal changes are required for the cells to migrate from tissues into the blood circulation, which is programmed by TGFβ signaling inducing EMT ([@B84]). The cells exhibiting EMT phenotype demonstrate loosened tight junctions and cell-to-cell adhesion to be ready to migrate ([@B30]; [@B84]).

![The complexity model scheme for the linkage between epithelial-mesenchymal transition (EMT) and cancer stem cell (CSC) concept. The CSC subpopulations exhibit the EMT phenotypes. The EMT and CSC pathways are regulated at gene level in several signaling pathways, where the plasticity is important for the cancer resistance.](fphar-11-00904-g001){#f1}

The Role of EMT and CSCs in Hypoxia {#s3_2}
-----------------------------------

Hypoxia is involved in the development and aggressiveness of solid tumors. The hypoxia-inducible factor (HIF), which is a main transcriptional regulator of cellular responses to hypoxia, regulate hypoxia responsive genes and contributes to increased cell proliferation, survival, angiogenesis, invasion and metastasis, as well as resistance to therapies. The EMT and CSCs are associated with the hypoxia in tumors, which plays an important role in the regulation and maintenance of the CSC phenotype. It has been demonstrated that the *in vitro* exposure of several human carcinoma cell lines induces EMT, likely due to mechanisms associated with HIF-1 activation ([@B28]; [@B36]; [@B92]). Moreover, it has been reported that HIF-1 promotes EMT of carcinoma cells in clear cell renal cell carcinoma, suppressing E-cadherin indirectly by inducing the expression of ZEB1 and ZEB2 and E2A immunoglobulin enhancer-binding factors E12/E47 (TCF3). Such inhibition leads to the mesenchymal characteristics to the carcinoma ([@B17]; [@B35]). These findings indicate the complex contribution of various factors contributing to EMT in carcinoma cells, and represent a formidable challenge for formulating therapeutic approaches to control the EMT in tumors.

Plasticity in EMT and CSCs {#s3_3}
--------------------------

CSCs are also phenotypically heterogeneous both inter- and intratumorally ([@B42]; [@B44]), which poses a significant challenge for developing targeted therapies. The heterogeneity of CSCs could be given by genetic mutations and epigenetic changes, or by microenvironmental differences, such as cell-cell interaction, cytokines, and hypoxia ([@B42]; [@B44]). Increasing evidence is also indicating that CSCs exist in anatomically and physiologically specialized environments within tumors, constituting niches that favor their survival ([@B55]; [@B8]). The reliance of the CSCs on niche signals is a general phenomenon and has been demonstrated in several tumors ([@B7]; [@B55]). CSCs can in turn modulate their niche, and utilize cell-signaling pathways for maintaining homeostatic processes, such as inflammation, EMT, hypoxia and angiogenesis ([@B7]; [@B55]). Consequently, the architecture and position of this niche are dynamic, and change with tumor development and progression, as well as with the applied treatments. Additionally, the microenvironment of the niche can revert nontumorigenic cancer cells into CSCs by EMT-associated processes, increasing tumor invasion and metastasis ([@B86]; [@B7]; [@B27]; [@B55]). Such dynamic interchange between cancer cells and CSC population suggests that therapies that are only active against CSCs may eventually result in the recurrence/resistance, if the residual differentiated cancer cells can repopulate the niche of CSCs. The cells with the mesenchymal phenotype release from the tissues to enter the circulation as circulating tumor cells (CTCs), where the mesenchymal-epithelial transition (MET) may occur to express the epithelial marker EPCAM in the blood circulation condition. However, it is still controversial that CTCs having high expression of EPCAM correlate with low survival, as shown in castration-resistant prostate cancer patients ([@B13]). CTCs themselves may have a variety of subpopulations ([@B51]). Therefore, targeted therapeutics aimed for tumor suppression should be able to reach the entire tumor, including CSC niches, at any step of tumor development and eliminate both cancer cells and CSCs with sufficient selectivity, for achieving safe and robust long-term responses.

Targeting EMT and CSCs by miRNAs {#s3_4}
--------------------------------

EMT and CSC formation have strong correlations in tumor cell invasion and metastasis. Moreover, EMT and CSCs are related to the acquisition of chemoresistance of tumor cells. Recently, miRNAs were reported to suppress chemoresistance in CSCs. For example, overexpression of miR-608, which targets ribonucleotide reductase large subunit M1 (RRM1) and cytidine deaminase (CDA), decreased the viability of the gemicitabine-resistant MIA-PaCa-RG4 and AsPC-RG2 pancreatic cancer cells ([@B56]). Overexpression of miR-204 significantly inhibited the metastasis and invasion of gastric cancer cells through the suppression of EMT by SNAI1 ([@B39]). miR-361-3p regulates ERK1/2-induced EMT *via* direct negative regulator of DUSP2 mRNA degradation in pancreatic ductal adenocarcinoma ([@B26]). Overexpression of miR-195-5p in DLD1 and HCT116 colon cancer cells repressed cell growth, colony formation, invasion, and migration, while the inhibition of miR-195-5p function contributed to aberrant cell proliferation, migration, invasion, and EMT ([@B70]). The emerging reports related to miRNA regulation may support the targeting EMT and CSCs by miRNAs ([@B71]).

Therapeutic Strategies for CSC Targeting {#s4}
========================================

Potential Therapeutic Strategies to Target CSCs {#s4_1}
-----------------------------------------------

The resistance of CSCs to conventional chemo- and radio-therapies, along with intratumoral heterogeneity and associated plasticity are the significant factors contributing to cancer treatment failure and recurrence. Accordingly, therapies that target CSCs and interrelated cellular hierarchy, represent an attractive direction toward developing robust cancer cures. Among different CSC targeting strategies, meddling with CSC surface markers, controlling drug efflux channels and transporters and targeting signaling pathways, such as Wnt, Hedgehog, and Notch pathways, produced encouraging pre-clinical results and are now in different phases of clinical trials ([@B31]; [@B2]; [@B16]; [@B64]). Drug-induced differentiation to convert CSCs to non-CSCs ([@B47]; [@B85]), or inducing MET ([@B53]; [@B52]) has also been experimentally confirmed as a practical therapeutic approach to sensitize this therapy-resistant subpopulation to chemotherapies. Several differentiation-inducing agents have shown their vast potential as in single-agent anticancer therapies in pre-clinical studies, however, equivalent responses have not always been observed in patients. These epigenetic modulators generally exert pleiotropic effects and have relatively low cytotoxicity on malignant cells; accordingly, their true therapeutic potential most likely lies in optimal combination with other anticancer drugs ([@B5]). In this respect, concomitant cytotoxic therapy with differentiation therapy is expected to prove as a promising therapeutic approach to eradicate this tumor-driving cell population and ultimately bring complete remission. In addition to the differentiation-inducing CSC targeting strategies, immunotherapy-based anti-CSC approaches are also receiving much research attention. Considering that co-inhibitory molecules and immune checkpoint ligands, such as programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2), are highly expressed on CSCs of various cancers, many research groups have also evaluated immunotherapeutic approaches to target CSCs. Among different immunotherapy-based strategies that have been assessed to target CSCs, adaptive T-cells, dendritic cell (DC)-based vaccines, oncolytic viruses, and immune checkpoint inhibitors are typical examples and have recently been reviewed elaborately by Badrinath and Yoo ([@B3]; [@B64]). Added to the strategies mentioned above; another rational approach of targeting CSCs is signified by the use of nanotechnology as an efficient tool for the detection and elimination of CSCs. Nanotechnology-based approach will be discussed elaborately in the following chapter.

Nanomedicines Targeting CSCs {#s4_2}
----------------------------

Nanotechnologies for disease management has already demonstrated significant potential in clinical oncology with several anticancer drug-loaded nanomedicines being already in clinical use ([@B83]; [@B1]). With a unique pharmacokinetics (PK)/pharmacodynamics (PD) profile, nanomedicine delivers many pharmacological advantages over conventional chemotherapy, such as improved bioavailability, reduced toxicity, and increased target-tissue selectivity ([@B59]). Nanomedicine has the potential for developing unprecedented therapies by controlling drug functions in a spatiotemporal manner ([@B10]), which allows for effective targeting to subpopulations in tumor tissues, as well as intracellular therapeutic targets. With CSC subpopulation in tumors accounting for resistance to therapies and tumor recurrence, institution of novel therapeutic strategies capable of eradicating the CSC fraction is central for achieving the robust responses and long-term patient survival. In this respect, nanomedicine has the potential to target CSCs for realizing effective cancer treatment outcome. For example, the polymeric micelle-based nanomedicine incorporating cisplatin (CDDP/m), which is currently in Phase III of clinical trials for treating pancreatic cancer ([@B9]), was able to eradicate both undifferentiated cell and differentiated cancer cell populations within tumors by controlled intratumoral and intracellular navigation ([@B88]). This effect was demonstrated in head and neck cancers, where a majority of late-stage cancer cases suffer tumor relapse following cisplatin treatment. Additionally, several nanomedicine-type approaches for both CSC-related therapy and diagnostics have been developed recently ([@B57]). Combination of thermo and chemotherapy utilizing multifunctional magnetic nanoparticles have been used to target CSCs for the effective cancer treatment ([@B40]). The nanomedicine containing miR-125b-5p to target EMT and CSCs effectively demonstrated the tumor inhibition *in vivo* ([@B22]). Another nanomedicine strategy includes co-loaded liposomes of cabazitaxel and CSC inhibitor silibinin to target CD44 receptors on CSCs ([@B43]). Strategies capable of enhancing the levels of nanomedicines in tumors and cancer cells could also promote the activity in CSC-rich tumors. Besides peptides or small molecules, the surface of nanomedicines can be modified with other ligands, such as antibodies, antibody fragments or aptamers, providing a versatile platform for targeting tumors and CSCs.

Conclusion {#s5}
==========

The CSCs exhibit a variety of features, some of which demonstrate EMT characteristics. CSCs contribute into the anticancer drug resistance leading to the recurrent of cancer, which may be one of the targets for the therapy. Signaling pathways in EMT and CSCs are possible targets for cancer treatment. Considering that these pathways in EMT and CSCs are also found in normal cells, specific targeting of the cancer is critical. There have been emerging evidences that miRNAs regulate various cellular phenotypic changes including EMT and CSCs, which may be one of the targets for cancer therapy. Varieties of novel therapeutics, including nanomedicine and immunotherapy, also have great possibilities for CSC targeting. Further advancement of CSC therapies in combination with several targeting strategies can be envisioned in the near future.
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